Breadcrumbs

Ca breast - oncology

Protocol Administration at chemotherapy unit level Review date
Breast trastuzumab subcutaneous Low September 2022

Adjuvant

Protocol Administration at chemotherapy unit level Review date
Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense Medium March 2020
Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) (dose dense) followed by PACLItaxel (dose dense) Medium September 2020
Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) followed by PACLItaxel (weekly) and trastuzumab (three weekly) Medium. Moves to low risk after completion of PACLitaxel treatment
March 2021
Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) followed by PACLItaxel (weekly) Medium September 2022
Breast adjuvant AC (DOXOrubicin CYCLOPHOSPHamide) three weekly Medium March 2020
Breast adjuvant anastrozole Low June 2022
Breast adjuvant anastrozole (early switch) Low September 2022
Breast adjuvant capecitabine (post neoadjuvant chemotherapy) Low September 2022
Breast adjuvant CMF classical (CYCLOPHOSPHamide methotrexate fluorouracil) Medium March 2021
Breast adjuvant D (DOCEtaxel) (Part 2 of FEC-D ) Medium September 2022
Breast adjuvant EC (epirubicin and CYCLOPHOSPHamide) Medium March 2020
Breast adjuvant exemestane Low September 2020
Breast adjuvant exemestane and goserelin Low September 2022
Breast adjuvant FEC (fluorouracil epirubicin CYCLOPHOSPHamide) (part 1 of FEC-D) Medium September 2022
Breast adjuvant FEC-D ((fluorouracil epirubicin CYCLOPHOSPHamide followed by DOCEtaxel) Medium September 2020
Breast adjuvant goserelin Low March 2021
Breast adjuvant letrozole Low September 2022
Breast adjuvant neratinib Low September 2022
Breast adjuvant PACLItaxel dose dense Medium March 2021
Breast adjuvant PACLItaxel weekly Medium September 2020
Breast adjuvant PACLItaxel weekly and trastuzumab three weekly Medium.  Moves to low risk after completion of PACLitaxel treatment September 2021
Breast adjuvant tamoxifen Low September 2022
Breast adjuvant TAC (DOCEtaxel DOXOrubicin CYCLOPHOSPHamide) Medium March 2020
Breast adjuvant TC (DOCEtaxel and CYCLOPHOSPHamide) Medium September 2020
Breast adjuvant TCH (DOCEtaxel cARBOplatin trastuzumab) Medium.  Moves to low risk after completion of PACLitaxel treatment March 2021
Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly Medium.  Moves to low risk after completion of PACLitaxel treatment September 2022
Breast adjuvant trastuzumab three weekly Low March 2020

Neoadjuvant

Protocol Administration at chemotherapy unit level Review date
Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense (Part 2) Medium September 2020
Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly Medium March 2021
Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly followed by DOCEtaxel three weekly Medium September 2022
Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly followed by PACLitaxel weekly Medium March 2021
Breast neoadjuvant cARBOplatin three weekly and PACLItaxel weekly (part 1) Medium March 2020
Breast neoadjuvant cARBOplatin three weekly and PACLItaxel weekly followed by AC (DOXOrubicin CYCLOPHOSPHamide) dose dense Medium September 2020
Breast neoadjuvant D (DOCEtaxel) (part 2 of FEC-D) Medium March 2021
Breast neoadjuvant DOCEtaxel three weekly (Part 2) Medium September 2022
Breast neoadjuvant DOCEtaxel, pertuzumab and trastuzumab Medium.  Moves to low risk after completion of PACLitaxel treatment March 2021
Breast neoadjuvant FEC (fluorouracil epirubicin CYCLOPHOSPHamide) (Part 1 of FEC-D) Medium March 2020
Breast neoadjuvant PACLitaxel weekly (part 2) Medium March 2021
Breast neoadjuvant PACLitaxel weekly, pertuzumab and trastuzumab three weekly Medium.  Moves to low risk after completion of PACLitaxel treatment September 2022
Breast neoadjuvant TAC (DOCEtaxel DOXOrubicin CYCLOPHOSPHamide) Medium September 2020
Breast neoadjuvant trastuzumab three weekly Low March 2021

Metastatic

Protocol Administration at chemotherapy unit level Review date
Breast metastatic AC (DOXOrubicin and CYCLOPHOSPHamide) Medium September 2022
Breast metastatic anastrozole Low September 2022
Breast metastatic capecitabine Low September 2022
Breast metastatic capecitabine and lapatinib Low March 2021
Breast metastatic capecitabine and trastuzumab Low September 2022
Breast metastatic cARBOplatin and Gemcitabine

Medium Day 1 - Low Day 8

March 2020
Breast metastatic CMF classical (CYCLOPHOSPHamide methotrexate fluorouracil) Medium September 2020
Breast metastatic denosumab Low September 2022
Breast metastatic DOCEtaxel and trastuzumab three weekly Medium.  Moves to low risk after completion of PACLitaxel treatment March 2021
Breast metastatic DOCEtaxel three weekly Medium September 2022
Breast metastatic DOCEtaxel, pertuzumab and trastuzumab Medium5.  Moves to low risk after completion of PACLitaxel treatment September 2022
Breast metastatic DOXOrubicin three weekly Medium September 2020
Breast metastatic DOXOrubicin weekly Medium March 2021
Breast metastatic epirubicin weekly
(for information on this protocol please contact the SA Health Cancer Drug Committee)
Medium  December 2021
Breast metastatic EC (epirubicin and CYCLOPHOSPHamide) Medium September 2022
Breast metastatic eribulin Medium March 2020
Breast metastatic everolimus and exemestane Low September 2020
Breast metastatic exemestane Low March 2021
Breast metastatic FEC (fluorouracil epirubicin CYCLOPHOSPHamide) Medium September 2022
Breast metastatic fulvestrant 4 Medium September 2022
Breast metastatic goserelin Low September 2020
Breast metastatic letrozole Low March 2021
Breast metastatic nab-PACLItaxel three weekly Medium September 2022
Breast metastatic nab-PACLItaxel weekly Medium March 2020
Breast metastatic olaparib Low September 2022
Breast metastatic PACLItaxel weekly Medium September 2020
Breast metastatic PACLItaxel weekly and trastuzumab three weekly Medium.  Moves to low risk after completion of PACLitaxel treatment March 2021
Breast metastatic PACLItaxel weekly, pertuzumab and trastuzumab three weekly Medium5. Moves to low risk after completion of PACLitaxel treatment September 2022
Breast metastatic palbociclib Low September 2022
Breast metastatic pegylated liposomal DOXOrubicin Medium March 2020
Breast metastatic ribociclib Low September 2022
Breast metastatic tamoxifen Low September 2020
Breast metastatic trastuzumab emtansine Medium 1 June 2022
Breast metastatic trastuzumab three weekly Low September 2022
Breast metastatic trastuzumab three weekly and vinORELBine (IV) Medium.  Moves to low risk after completion of PACLitaxel treatment March 2020
Breast metastatic trastuzumab three weekly and vinORELBine (oral) Low March 2021
Breast metastatic vinORELBine (IV) Medium September 2021
Breast metastatic vinORELBine (oral) Low March 2021
Breast metastatic zoledronic acid Low September 2022

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top